WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
A total of 17 labs will be operational across the country by this month
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
State-of-the-art laboratory to support ingredient and specialty chemical innovation, product formulation application development and more sustainable solutions across Europe and beyond
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Subscribe To Our Newsletter & Stay Updated
